[1]
“Radiolabeled Peptide as Diagnostic, Therapeutic, and Theranostic agents for Prostate Cancer: Systematic Literature Review”, PharmRep, vol. 1, no. 1, Mar. 2022, doi: 10.33096/pharmrep.v1i1.174.